Abstract
Purpose To assess if a combination therapy (MDT and TESIs), administered while being on the waiting list for lumbar herniated disc surgery, is effective and cost-effective compared to no intervention (i.e., usual care).
Study design Multicentre randomized controlled trial with economic evaluation and one-year follow-up.
Patient Sample Seventy-two adult patients on a waiting list for lumbar herniated disc surgery.
Outcome Measures Primary outcome was undergoing lumbar disc surgery during follow-up (yes/no). Secondary outcomes included back and leg pain intensity (NPRS), physical functioning (RMDQ-23), self-perceived recovery (GPE), and health-related quality of life (EQ-5D-5L). Total societal and total healthcare were measured.
Methods Participants were randomly assigned to combination therapy (intervention group, n=34) or no intervention (control group, n=38).
Results Twenty-nine out of 38 control group patients and 11 out of 34 intervention group patients received surgery. The adjusted odds ratio of receiving surgery in the intervention group compared to the control group was 0.09 (95%CI: 0.02 to 0.35) and the adjusted risk ratio 0.29 (95%CI: 0.08 to 0.69). There were no differences in clinical effects between both groups. Surgical, total societal, and total healthcare costs were on average €1,969, €1,754, and €2,363 lower in the intervention group, respectively. The combination therapy's probability of being cost-effective was moderate (≤0.66) across a range of willingness-to-pay values from €20,000/QALY to €80,000/QALY, from a societal perspective.
Conclusion Patients on the waiting list for lumbar disc surgery and who are open to postpone surgery, may benefit from the combination therapy intervention.
| Original language | English |
|---|---|
| Pages (from-to) | 1309-1321 |
| Number of pages | 13 |
| Journal | The Spine Journal |
| Volume | 25 |
| Issue number | 7 |
| Early online date | 31 Jan 2025 |
| DOIs | |
| Publication status | Published - Jul 2025 |
Funding
ZorgOnderzoek Nederlands Medische Wetenschappen (ZonMw) & Rugpoli funded the PLUS-study. Author disclosures: ENM: Nothing to disclose. HVH: Nothing to disclose. JMVD: Nothing to disclose. MVK: Nothing to disclose. AJB: Nothing to disclose. CVL: Scientific Advisory Board/Other Office: Rijndam Rehabilitation Centre Advisory Board, Excom Eurospine, Board CSRS Europe, President Netherlands Association for Neurosurgery, unpaid (none); Grants: Thromboembolic complications in Neurosurgery (Covidien), Fundamentals of radiculopathy (YM Fund/Achmea health insurance and Eurospine), Stop Smoking (Achmea), 5yr FU disc prosthesis in cervical spine surgery (CSRS E). faculty for EANS, CSRS, Eurospine (none). FH: Consulting: Boston Scientific (None); Speaking and/or Teaching Arrangements: ABBOTT Grunenthal (None). MWVT: Grant: ZonMw (F). HAKK: Nothing to disclose. SR: Nothing to disclose. ML: Nothing to disclose. NAVDG: Nothing to disclose. CFEH: Nothing to disclose. PLP: Nothing to disclose. EMK: Nothing to disclose. MP: Nothing to disclose. RWJGO: Grant: ZonMW (F); ZonMW (G); DBRIC (D); NVMT (F); DBRIC (F); ZonMW (F).
| Funders | Funder number |
|---|---|
| YM Fund | |
| ZorgOnderzoek Nederlands Medische Wetenschappen | |
| Centre for Studies in Religion and Society, University of Victoria | |
| Rijndam Rehabilitation Centre Advisory Board | |
| NVMT | |
| ZonMw | |
| Covidien | |
| Achmea health insurance and Eurospine | |
| DBRIC | |
| Netherlands Association for Neurosurgery | |
| Fundamentals of radiculopathy |
Keywords
- Effectiveness
- Cost-effectiveness
- Lumbar Disc Herniation
- Lumbar Disc surgery
- Mechanical Diagnosis Therapy
- Steroid Injections